Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 1
2022 1
2023 3
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Liver Fat Quantification: When do We Need It?
Piscaglia F, Stefanini B, Terzi E, Marseglia M, Cantisani V. Piscaglia F, et al. Among authors: marseglia m. Ultraschall Med. 2023 Apr;44(2):120-124. doi: 10.1055/a-2015-5693. Epub 2023 Mar 30. Ultraschall Med. 2023. PMID: 36996835 Free article. English, German. No abstract available.
Characteristics and outcome of anti-hepatitis D virus positive patients with hepatocellular carcinoma.
Giannini EG, Pasta A, Pieri G, Plaz Torres MC, Marseglia M, Pelizzaro F, Sangiovanni A, Cabibbo G, Ghittoni G, Di Marco M, Foschi FG, Guarino M, Biasini E, Saitta C, Campani C, Svegliati-Baroni G, Gasbarrini A, Brunetto MR, Magalotti D, Azzaroli F, Mega A, Sacco R, Nardone G, Sacerdoti D, Masotto A, Vidili G, Bucci L, Vitale A, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group. Giannini EG, et al. Among authors: marseglia m. Liver Int. 2024 Mar 1. doi: 10.1111/liv.15855. Online ahead of print. Liver Int. 2024. PMID: 38426262
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma.
Camera S, Rimini M, Rossari F, Tada T, Suda G, Shimose S, Kudo M, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Salani F, Marseglia M, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone M, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Lonardi S, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Persano M, Foti S, Piscaglia F, Scartozzi M, Cascinu S, Casadei-Gardini A. Camera S, et al. Among authors: marseglia m. Target Oncol. 2024 Jan;19(1):29-39. doi: 10.1007/s11523-023-01029-6. Epub 2024 Jan 22. Target Oncol. 2024. PMID: 38252195
Prediction of cardiovascular risk in patients with hepatocellular carcinoma receiving anti-angiogenic drugs: lessons from sorafenib.
Stefanini B, Tovoli F, Trevisani F, Marseglia M, Di Costanzo GG, Cabibbo G, Sacco R, Pellizzaro F, Pressiani T, Chen R, Ponziani FR, Foschi FG, Magini G, Granito A, Piscaglia F; Italian Liver Cancer (ITA.LI.CA) group. Stefanini B, et al. Among authors: marseglia m. Intern Emerg Med. 2024 Mar 29. doi: 10.1007/s11739-024-03578-8. Online ahead of print. Intern Emerg Med. 2024. PMID: 38551755